

Contents

List of Contributors *XV*

About the Series Editors *XXIII*

- 1 Integrative Analysis of Omics Data** *1*
Tobias Österlund, Marija Cvijovic, and Erik Kristiansson
Summary *1*
- 1.1 Introduction *1*
- 1.2 Omics Data and Their Measurement Platforms *4*
- 1.2.1 Omics Data Types *4*
- 1.2.2 Measurement Platforms *5*
- 1.3 Data Processing: Quality Assessment, Quantification, Normalization, and Statistical Analysis *6*
- 1.3.1 Quality Assessment *7*
- 1.3.2 Quantification *9*
- 1.3.3 Normalization *10*
- 1.3.4 Statistical Analysis *11*
- 1.4 Data Integration: From a List of Genes to Biological Meaning *12*
- 1.4.1 Data Resources for Constructing Gene Sets *13*
- 1.4.1.1 Gene Ontology Terms *13*
- 1.4.1.2 KEGG and Reactome *13*
- 1.4.1.3 Genome-Scale Metabolic Reconstructions *14*
- 1.4.2 Gene Set Analysis *14*
- 1.4.2.1 Gene Set Overenrichment Tests *16*
- 1.4.2.2 Rank-Based Enrichment Tests *16*
- 1.4.3 Networks and Network Topology *17*
- 1.5 Outlook and Perspectives *18*
- References *19*
- 2 ¹³C Flux Analysis in Biotechnology and Medicine** *25*
Yi Ern Cheah, Clinton M. Hasenour, and Jamey D. Young
- 2.1 Introduction *25*
- 2.1.1 Why Study Metabolic Fluxes? *25*
- 2.1.2 Why are Isotope Tracers Important for Flux Analysis? *26*

| | | |
|----------|---|-----------|
| 2.1.3 | How are Fluxes Determined? | 28 |
| 2.2 | Theoretical Foundations of ^{13}C MFA | 29 |
| 2.2.1 | Elementary Metabolite Units (EMUs) | 30 |
| 2.2.2 | Flux Uncertainty Analysis | 31 |
| 2.2.3 | Optimal Design of Isotope Labeling Experiments | 32 |
| 2.2.4 | Isotopically Nonstationary MFA (INST-MFA) | 34 |
| 2.3 | Metabolic Flux Analysis in Biotechnology | 36 |
| 2.3.1 | ^{13}C MFA for Host Characterization | 36 |
| 2.3.2 | ^{13}C MFA for Pinpointing Yield Losses and Futile Cycles | 39 |
| 2.3.3 | ^{13}C MFA for Bottleneck Identification | 41 |
| 2.4 | Metabolic Flux Analysis in Medicine | 42 |
| 2.4.1 | Liver Glucose and Oxidative Metabolism | 43 |
| 2.4.2 | Cancer Cell Metabolism | 47 |
| 2.4.3 | Fuel Oxidation and Anaplerosis in the Heart | 48 |
| 2.4.4 | Metabolism in Other Tissues: Pancreas, Brain, Muscle, Adipose, and Immune Cells | 49 |
| 2.5 | Emerging Challenges for ^{13}C MFA | 50 |
| 2.5.1 | Theoretical and Computational Advances: Multiple Tracers, Co-culture MFA, Dynamic MFA | 50 |
| 2.5.2 | Genome-Scale ^{13}C MFA | 51 |
| 2.5.3 | New Measurement Strategies | 52 |
| 2.5.4 | High-Throughput MFA | 53 |
| 2.5.5 | Application of MFA to Industrial Bioprocesses | 53 |
| 2.5.6 | Integrating MFA with Omics Measurements | 54 |
| 2.6 | Conclusion | 55 |
| | Acknowledgments | 55 |
| | Disclosure | 55 |
| | References | 55 |
| 3 | Metabolic Modeling for Design of Cell Factories | 71 |
| | <i>Mingyuan Tian, Prashant Kumar, Sanjan T. P. Gupta, and Jennifer L. Reed</i> | |
| | Summary | 71 |
| 3.1 | Introduction | 71 |
| 3.2 | Building and Refining Genome-Scale Metabolic Models | 72 |
| 3.2.1 | Generate a Draft Metabolic Network (Step 1) | 74 |
| 3.2.2 | Manually Curate the Draft Metabolic Network (Step 2) | 75 |
| 3.2.3 | Develop a Constraint-Based Model (Step 3) | 77 |
| 3.2.4 | Revise the Metabolic Model through Reconciliation with Experimental Data (Step 4) | 79 |
| 3.2.5 | Predicting the Effects of Genetic Manipulations | 81 |
| 3.3 | Strain Design Algorithms | 83 |
| 3.3.1 | Fundamentals of Bilevel Optimization | 84 |
| 3.3.2 | Algorithms Involving Only Gene/Reaction Deletions | 94 |
| 3.3.3 | Algorithms Involving Gene Additions | 94 |
| 3.3.4 | Algorithms Involving Gene Over/Underexpression | 95 |

| | | |
|----------|---|------------|
| 3.3.5 | Algorithms Involving Cofactor Changes | 98 |
| 3.3.6 | Algorithms Involving Multiple Design Criteria | 99 |
| 3.4 | Case Studies | 100 |
| 3.4.1 | Strains Producing Lactate | 100 |
| 3.4.2 | Strains Co-utilizing Sugars | 100 |
| 3.4.3 | Strains Producing 1,4-Butanediol | 102 |
| 3.5 | Conclusions | 103 |
| | Acknowledgments | 103 |
| | References | 104 |
| 4 | Genome-Scale Metabolic Modeling and <i>In silico</i> Strain Design of <i>Escherichia coli</i> | 109 |
| | <i>Meiyappan Lakshmanan, Na-Rae Lee, and Dong-Yup Lee</i> | |
| 4.1 | Introduction | 109 |
| 4.2 | The COBRA Approach | 110 |
| 4.3 | History of <i>E. coli</i> Metabolic Modeling | 111 |
| 4.3.1 | Pre-genomic-era Models | 111 |
| 4.3.2 | Genome-Scale Models | 112 |
| 4.4 | <i>In silico</i> Model-Based Strain Design of <i>E. coli</i> Cell Factories | 115 |
| 4.4.1 | Gene Deletions | 127 |
| 4.4.2 | Gene Up/Downregulations | 127 |
| 4.4.3 | Gene Insertions | 128 |
| 4.4.4 | Cofactor Engineering | 128 |
| 4.4.5 | Other Approaches | 128 |
| 4.5 | Future Directions of Model-Guided Strain Design in <i>E. coli</i> | 129 |
| | References | 130 |
| 5 | Accelerating the Drug Development Pipeline with Genome-Scale Metabolic Network Reconstructions | 139 |
| | <i>Bonnie V. Dougherty, Thomas J. Moutinho Jr., and Jason Papin</i> | |
| | Summary | 139 |
| 5.1 | Introduction | 139 |
| 5.1.1 | Drug Development Pipeline | 140 |
| 5.1.2 | Overview of Genome-Scale Metabolic Network Reconstructions | 140 |
| 5.1.3 | Analytical Tools and Mathematical Evaluation | 141 |
| 5.1.3.1 | Flux Balance Analysis (FBA) | 141 |
| 5.1.3.2 | Flux Variability Analysis (FVA) | 142 |
| 5.2 | Metabolic Reconstructions in the Drug Development Pipeline | 142 |
| 5.2.1 | Target Identification | 143 |
| 5.2.2 | Drug Side Effects | 145 |
| 5.3 | Species-Level Microbial Reconstructions | 146 |
| 5.3.1 | Microbial Reconstructions in the Antibiotic Development Pipeline | 146 |
| 5.3.1.1 | Applications in the Drug Development Pipeline | 146 |

| | | |
|----------|--|------------|
| 5.3.2 | Metabolic-Reconstruction-Facilitated Rational Drug Target Identification | 147 |
| 5.3.2.1 | Targeting Genes Essential for Biomass Production | 147 |
| 5.3.2.2 | Targeting Virulence Factors | 147 |
| 5.3.2.3 | Metabolite-centric Targeting | 148 |
| 5.3.3 | Repurposing and Expanding Utility of Antibiotics | 149 |
| 5.3.3.1 | Virtual Drug Screens Informed by Metabolic Reconstructions | 149 |
| 5.3.3.2 | Limiting Resistance with Drug Combinations | 149 |
| 5.3.3.3 | Improving Treatment Options by Increasing Sensitivity to Antibiotics | 150 |
| 5.3.4 | Improving Toxicity Screens with the Human Metabolic Network Reconstruction | 150 |
| 5.4 | The Human Reconstruction | 151 |
| 5.4.1 | Approaches for the Human Reconstruction | 152 |
| 5.4.2 | Target Identification | 152 |
| 5.4.2.1 | Drug Targeting in Cancer | 152 |
| 5.4.2.2 | Drug Targeting in Metabolic Diseases | 153 |
| 5.4.3 | Toxicity and Other Side Effects | 154 |
| 5.5 | Community Models | 155 |
| 5.5.1 | Host–Pathogen Community Models | 155 |
| 5.5.2 | Eukaryotic Community Models | 156 |
| 5.6 | Personalized Medicine | 156 |
| 5.7 | Conclusion | 157 |
| | References | 158 |
| 6 | Computational Modeling of Microbial Communities | 163 |
| | <i>Siu H. J. Chan, Margaret Simons, and Costas D. Maranas</i> | |
| | Summary | 163 |
| 6.1 | Introduction | 163 |
| 6.1.1 | Microbial Communities | 163 |
| 6.1.2 | Modeling Microbial Communities | 165 |
| 6.1.3 | Model Structures | 165 |
| 6.1.4 | Quantitative Approaches | 166 |
| 6.2 | Ecological Models | 168 |
| 6.2.1 | Generalized Predator–Prey Model | 169 |
| 6.2.2 | Evolutionary Game Theory | 170 |
| 6.2.3 | Models Including Additional Dimensions | 171 |
| 6.2.4 | Advantages and Disadvantages | 171 |
| 6.3 | Genome-Scale Metabolic Models | 172 |
| 6.3.1 | Introduction and Applications | 172 |
| 6.3.2 | Genome-Scale Metabolic Modeling of Microbial Communities | 174 |
| 6.3.3 | Simulation of Microbial Communities Assuming Steady State | 175 |
| 6.3.3.1 | Predicting Interactions Using FBA | 175 |
| 6.3.3.2 | Identifying Minimal Media by Mixed Integer Linear Programming | 176 |

| | | |
|----------|--|------------|
| 6.3.3.3 | Pareto Optimality Analysis by FBA | 176 |
| 6.3.3.4 | Modeling Chemostat Co-culture | 177 |
| 6.3.3.5 | Community FBA with Community Mass Balance | 177 |
| 6.3.4 | Dynamic Simulation of Multispecies Models | 177 |
| 6.3.5 | Spatial and Temporal Modeling of Communities | 178 |
| 6.3.6 | Using Bilevel Optimization to Capture Multiple Objective Functions | 179 |
| 6.3.6.1 | OptCom | 179 |
| 6.3.6.2 | d-OptCom | 181 |
| 6.3.6.3 | CASINO Toolbox | 181 |
| 6.3.6.4 | Advantages and Disadvantages | 182 |
| 6.3.6.5 | Current Challenges and Future Directions | 182 |
| 6.4 | Concluding Remarks | 183 |
| | References | 183 |
| 7 | Drug Targeting of the Human Microbiome | 191 |
| | <i>Hua Ling, Jee L. Foo, Gourvindu Saxena, Sanjay Swarup, and Matthew W. Chang</i> | |
| | Summary | 191 |
| 7.1 | Introduction | 191 |
| 7.2 | The Human Microbiome | 192 |
| 7.3 | Association of the Human Microbiome with Human Diseases | 194 |
| 7.3.1 | Nasal–Sinus Diseases | 194 |
| 7.3.2 | Gut Diseases | 194 |
| 7.3.3 | Cardiovascular Diseases | 196 |
| 7.3.4 | Metabolic Disorders | 196 |
| 7.3.5 | Autoimmune Disorders | 197 |
| 7.3.6 | Lung Diseases | 197 |
| 7.3.7 | Skin Diseases | 197 |
| 7.4 | Drug Targeting of the Human Microbiome | 198 |
| 7.4.1 | Prebiotics | 198 |
| 7.4.2 | Probiotics | 200 |
| 7.4.3 | Antimicrobials | 201 |
| 7.4.3.1 | Antibiotics | 201 |
| 7.4.3.2 | Antimicrobial Peptides | 202 |
| 7.4.4 | Signaling Inhibitors | 202 |
| 7.4.5 | Metabolites | 203 |
| 7.4.5.1 | Short-Chain Fatty Acids | 203 |
| 7.4.5.2 | Bile Acids | 203 |
| 7.4.6 | Metabolite Receptors and Enzymes | 204 |
| 7.4.6.1 | Metabolite Receptors | 204 |
| 7.4.6.2 | Metabolic Enzymes | 204 |
| 7.4.7 | Microbiome-Aided Drug Metabolism | 205 |
| 7.4.7.1 | Drug Delivery and Release | 205 |

| | | |
|-----------|---|------------|
| 7.4.7.2 | Drug Toxicity | 206 |
| 7.4.8 | Immune Modulators | 206 |
| 7.4.9 | Synthetic Commensal Microbes | 207 |
| 7.5 | Future Perspectives | 207 |
| 7.6 | Concluding Remarks | 208 |
| | Acknowledgments | 208 |
| | References | 209 |
| 8 | Toward Genome-Scale Models of Signal Transduction Networks | 215 |
| | <i>Ulrike Münzner, Timo Lubitz, Edda Klipp, and Marcus Krantz</i> | |
| 8.1 | Introduction | 215 |
| 8.2 | The Potential of Network Reconstruction | 219 |
| 8.3 | Information Transfer Networks | 222 |
| 8.4 | Approaches to Reconstruction of ITNs | 225 |
| 8.5 | The rxncon Approach to ITNWR | 230 |
| 8.6 | Toward Quantitative Analysis and Modeling of Large ITNs | 234 |
| 8.7 | Conclusion and Outlook | 236 |
| | Acknowledgments | 236 |
| | Glossary | 237 |
| | References | 238 |
| 9 | Systems Biology of Aging | 243 |
| | <i>Johannes Borgqvist, Riccardo Dainese, and Marija Cvijovic</i> | |
| | Summary | 243 |
| 9.1 | Introduction | 243 |
| 9.2 | The Biology of Aging | 245 |
| 9.3 | The Mathematics of Aging | 249 |
| 9.3.1 | Databases Devoted to Aging Research | 249 |
| 9.3.2 | Mathematical Modeling in Aging Research | 249 |
| 9.3.3 | Distribution of Damaged Proteins during Cell Division: A Mathematical Perspective | 256 |
| 9.3.3.1 | Cell Growth | 256 |
| 9.3.3.2 | Cell Death | 257 |
| 9.3.3.3 | Cell Division | 257 |
| 9.4 | Future Challenges | 260 |
| | Conflict of Interest | 262 |
| | References | 262 |
| 10 | Modeling the Dynamics of the Immune Response | 265 |
| | <i>Elena Abad, Pablo Villoslada, and Jordi García-Ojalvo</i> | |
| 10.1 | Background | 265 |
| 10.2 | Dynamics of NF- κ B Signaling | 266 |
| 10.2.1 | Functional Role and Regulation of NF- κ B | 266 |

| | | |
|-----------|---|------------|
| 10.2.2 | Dynamics of the NF- κ B Response to Cytokine Stimulation | 267 |
| 10.3 | JAK/STAT Signaling | 273 |
| 10.3.1 | Functional Roles of the STAT Proteins | 273 |
| 10.3.2 | Regulation of the JAK/STAT Pathway | 274 |
| 10.3.3 | Multiplicity and Cross-talk in JAK/STAT Signaling | 275 |
| 10.3.4 | Early Modeling of STAT Signaling | 276 |
| 10.3.5 | Minimal Models of STAT Activation Dynamics | 277 |
| 10.3.6 | Cross-talk with Other Immune Pathways | 279 |
| 10.3.7 | Population Dynamics of the Immune System | 281 |
| 10.4 | Conclusions | 282 |
| | Acknowledgments | 283 |
| | References | 283 |
| 11 | Dynamics of Signal Transduction in Single Cells Quantified by Microscopy | 289 |
| | <i>Min Ma, Nadim Mira, and Serge Pelet</i> | |
| 11.1 | Introduction | 289 |
| 11.2 | Single-Cell Measurement Techniques | 291 |
| 11.2.1 | Flow Cytometry | 291 |
| 11.2.2 | Mass Cytometry | 291 |
| 11.2.3 | Single-Cell Transcriptomics | 292 |
| 11.2.4 | Single-Cell Mass Spectrometry | 292 |
| 11.2.5 | Live-Cell Imaging | 292 |
| 11.3 | Microscopy | 293 |
| 11.3.1 | Epi-Fluorescence Microscopy | 294 |
| 11.3.2 | Fluorescent Proteins | 295 |
| 11.3.3 | Relocation Sensors | 295 |
| 11.3.4 | Förster Resonance Energy Transfer | 298 |
| 11.4 | Imaging Signal Transduction | 300 |
| 11.4.1 | Quantifying Small Molecules | 300 |
| 11.4.2 | Monitoring Enzymatic Activity | 301 |
| 11.4.2.1 | Endogenous Relocation Sensors | 301 |
| 11.4.2.2 | Passive Relocation Sensors | 302 |
| 11.4.2.3 | Active Relocation Sensors | 303 |
| 11.4.2.4 | FRET Biosensors | 304 |
| 11.4.3 | Probing Protein–Protein Interactions | 304 |
| 11.4.3.1 | FRET in Protein Complexes | 304 |
| 11.4.3.2 | Bimolecular Fluorescence Complementation | 305 |
| 11.4.3.3 | Dimerization-Dependent FP | 306 |
| 11.4.4 | Measuring Protein Synthesis | 307 |
| 11.4.4.1 | mRNA Transcription | 307 |
| 11.4.4.2 | Protein Synthesis | 308 |
| 11.4.4.3 | Expression Dynamics Visualized by Protein Relocation | 311 |

| | | |
|-----------|--|------------|
| 11.5 | Conclusions | 311 |
| | References | 312 |
| 12 | Image-Based <i>In silico</i> Models of Organogenesis | 319 |
| | <i>Harold F. Gómez, Lada Georgieva, Odysse Michos, and Dagmar Iber</i> | |
| | Summary | 319 |
| 12.1 | Introduction | 319 |
| 12.2 | Typical Workflow of Image-Based <i>In silico</i> Modeling Experiments | 320 |
| 12.2.1 | <i>In silico</i> Models of Organogenesis | 322 |
| 12.2.2 | Imaging as a Source of (Semi-)Quantitative Data | 323 |
| 12.2.2.1 | Imaging a Growing Organ | 324 |
| 12.2.3 | Image Analysis and Quantification | 326 |
| 12.2.4 | Computational Simulations of Models Describing Organogenesis | 328 |
| 12.2.5 | Image-Based Parameter Estimation | 329 |
| 12.2.6 | <i>In silico</i> Model Validation and Exchange | 329 |
| 12.2.6.1 | <i>In silico</i> Model Validation | 329 |
| 12.2.6.2 | Model Exchange via the Systems Biology Markup Language (SBML) | 330 |
| 12.3 | Application: Image-Based Modeling of Branching Morphogenesis | 331 |
| 12.3.1 | Image-Based Model Selection | 331 |
| 12.4 | Future Avenues | 334 |
| | References | 334 |
| 13 | Progress toward Quantitative Design Principles of Multicellular Systems | 341 |
| | <i>Eduardo P. Olimpio, Diego R. Gomez-Alvarez, and Hyun Youk</i> | |
| | Summary | 341 |
| 13.1 | Toward Quantitative Design Principles of Multicellular Systems | 341 |
| 13.2 | Breaking Multicellular Systems into Distinct Functional and Spatial Modules May Be Possible | 342 |
| 13.3 | Communication among Cells as a Means of Cell–Cell Interaction | 346 |
| 13.4 | Making Sense of the Combinatorial Possibilities Due to Many Ways that Cells Can Be Arranged in Space | 350 |
| 13.5 | From Individual Cells to Collective Behaviors of Cell Populations | 352 |
| 13.6 | Tuning Multicellular Behaviors | 355 |
| 13.7 | A New Framework for Quantitatively Understanding Multicellular Systems | 359 |
| | Acknowledgments | 361 |
| | References | 362 |

| | | |
|-----------|--|------------|
| 14 | Precision Genome Editing for Systems Biology – A Temporal Perspective | 367 |
| | <i>Franziska Voellmy and Rune Linding</i> | |
| | Summary | 367 |
| 14.1 | Early Techniques in DNA Alterations | 367 |
| 14.2 | Zinc-Finger Nucleases | 369 |
| 14.3 | TALENs | 369 |
| 14.4 | CRISPR-Cas9 | 370 |
| 14.5 | Considerations of Gene-Editing Nuclease Technologies | 372 |
| 14.5.1 | Repairing Nuclease-Induced DNA Damage | 372 |
| 14.5.2 | Nuclease Specificity | 373 |
| 14.6 | Applications | 376 |
| 14.6.1 | CRISPR Nuclease Genome-Wide Loss-of-Function Screens (CRISPRn) | 377 |
| 14.6.2 | CRISPR Interference: CRISPRi | 378 |
| 14.6.3 | CRISPR Activation: CRISPRa | 378 |
| 14.6.4 | Further Scalable Additions to the CRISPR-Cas Gene Editing Tool Arsenal | 379 |
| 14.6.5 | <i>In vivo</i> Applications | 379 |
| 14.6.5.1 | Animal Disease Models | 379 |
| 14.6.5.2 | Gene Therapy | 379 |
| 14.7 | A Focus on the Application of Genome-Engineering Nucleases on Chromosomal Rearrangements | 380 |
| 14.7.1 | Introduction to Chromosomal Rearrangements: The First Disease-Related Translocation | 380 |
| 14.7.2 | A Global Look at the Mechanisms behind Chromosomal Rearrangements | 382 |
| 14.7.3 | Creating Chromosomal Rearrangements Using CRISPR-Cas | 383 |
| 14.8 | Future Perspectives | 384 |
| | References | 384 |
| | Index | 393 |

